Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03087448
Recruitment Status : Recruiting
First Posted : March 22, 2017
Last Update Posted : July 7, 2020
Sponsor:
Collaborators:
Novartis Pharmaceuticals
University of California, Davis
Information provided by (Responsible Party):
University of California, San Francisco

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 30, 2021
Estimated Study Completion Date : June 20, 2022